Amgen shares plummeted as the biotech company released disappointing trial results for its weight-loss experimental drug. The trial showed that many patients stopped taking the shot due to gastrointestinal distress, raising concerns about its safety and efficacy.
Source: https://www.barrons.com/articles/amgen-stock-weight-loss-gastrointestinal-17d28fdf